结肠癌患者术前血清纤连蛋白-3水平降低。
Decreased preoperative serum fibulin-3 levels in colon cancer patients.
作者信息
Simsek O, Kocael A, Kemik A, Vatankulu B, Kocael P, Halac M, Ulualp K, Sonmezoglu K
机构信息
Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
出版信息
Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4076-80.
OBJECTIVE
Fibulin-3 is known to play a role in tumor cell malignancy, invasion and metastasis, as well as in the clinical progression of tumors. This study aimed to assess serum fibulin-3 levels in patients with colon cancer compared with healthy controls and its relationship to demographics and tumor pathology.
PATIENTS AND METHODS
A total of 80 patients (mean age, 58.99 years; 42% males) with colon cancer and 50 controls (mean age, 57.75; 55% males) were included. Serum levels of fibulin-3 were determined using a commercially available sandwich ELISA (Enzyme-Linked ImmunoSorbent Assay).
RESULTS
Preoperative serum fibulin-3 levels were significantly lower in the group of patients with colon cancer (mean, 35.91 ng/mL; range, 10-73 ng/mL) compared with the control group (mean, 96.68 ng/mL; range, 57-168 ng/mL).
CONCLUSIONS
It was concluded that fibulin-3 is expressed at a lower level in colon cancer, and it can serve as a marker for advanced colon cancer.
目的
已知纤连蛋白-3在肿瘤细胞恶性、侵袭和转移以及肿瘤临床进展中发挥作用。本研究旨在评估结肠癌患者与健康对照者的血清纤连蛋白-3水平，及其与人口统计学和肿瘤病理学的关系。
患者与方法
共纳入80例结肠癌患者（平均年龄58.99岁；42%为男性）和50例对照者（平均年龄57.75岁；55%为男性）。使用市售夹心酶联免疫吸附测定法（ELISA）测定血清纤连蛋白-3水平。
结果
与对照组（平均96.68 ng/mL；范围57 - 168 ng/mL）相比，结肠癌患者组术前血清纤连蛋白-3水平显著降低（平均35.91 ng/mL；范围10 - 73 ng/mL）。
结论
得出结论，纤连蛋白-3在结肠癌中表达水平较低，可作为晚期结肠癌的标志物。
Zotero 插件